Q4 2021 Earnings Estimate for Sientra, Inc. (NASDAQ:SIEN) Issued By Colliers Securities

Sientra, Inc. (NASDAQ:SIEN) – Colliers Securities boosted their Q4 2021 EPS estimates for shares of Sientra in a research note issued to investors on Tuesday, January 11th. Colliers Securities analyst K. Bauser now forecasts that the medical instruments supplier will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.21). Colliers Securities has a “Buy” rating and a $10.00 price objective on the stock. Colliers Securities also issued estimates for Sientra’s FY2022 earnings at ($0.73) EPS.

Separately, Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Wednesday, November 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Sientra currently has an average rating of “Buy” and a consensus price target of $9.35.

Shares of Sientra stock opened at $3.03 on Thursday. The stock has a market capitalization of $176.11 million, a P/E ratio of -1.63 and a beta of 2.04. The company has a quick ratio of 1.33, a current ratio of 2.05 and a debt-to-equity ratio of 1.51. The company has a 50-day simple moving average of $4.09 and a 200 day simple moving average of $5.71. Sientra has a 12-month low of $2.89 and a 12-month high of $9.14.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Wednesday, November 10th. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.18. The business had revenue of $19.62 million during the quarter, compared to analyst estimates of $18.10 million. During the same quarter in the prior year, the company posted ($0.33) EPS.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. OLD Mission Capital LLC bought a new position in shares of Sientra in the 3rd quarter valued at about $219,000. New York State Common Retirement Fund boosted its stake in shares of Sientra by 46.0% in the 2nd quarter. New York State Common Retirement Fund now owns 49,624 shares of the medical instruments supplier’s stock valued at $395,000 after purchasing an additional 15,624 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Sientra by 21.1% in the 2nd quarter. Sei Investments Co. now owns 38,945 shares of the medical instruments supplier’s stock valued at $310,000 after purchasing an additional 6,787 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Sientra by 7.0% in the 2nd quarter. Principal Financial Group Inc. now owns 83,782 shares of the medical instruments supplier’s stock valued at $667,000 after purchasing an additional 5,475 shares during the last quarter. Finally, Birchview Capital LP bought a new position in shares of Sientra in the 2nd quarter valued at about $318,000. Hedge funds and other institutional investors own 90.55% of the company’s stock.

In other Sientra news, CEO Ronald Menezes sold 78,498 shares of the firm’s stock in a transaction dated Wednesday, November 10th. The shares were sold at an average price of $5.67, for a total value of $445,083.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Hove Caroline F. Van sold 6,087 shares of the firm’s stock in a transaction dated Wednesday, November 10th. The shares were sold at an average price of $5.67, for a total transaction of $34,513.29. The disclosure for this sale can be found here. Company insiders own 1.10% of the company’s stock.

Sientra Company Profile

Sientra, Inc operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM.

Further Reading: What is systematic risk?

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.